Abstract: The present disclosure relates to a bioparticle measuring method including detecting a signal from a first measurement sample and a signal from a second measurement sample, wherein the first measurement sample is prepared by mixing a first sample containing a bioparticle sampled from a specimen with a detector capable of binding to the bioparticle and containing a labeled substance, in the presence of an inhibitor capable of binding to the bioparticle and containing none of the labeled substance. The second measurement sample is prepared by mixing a second sample sampled from the same specimen independently from the first sample with the detector, under a condition that the inhibitor is substantially absent. A measurement result is then calculated from the detected signals from the first and second measurement samples.

Abstract: The present disclosure relates to a bioparticle measuring method including forming on a solid phase a complex of a sample containing a bioparticle sampled from a specimen, a capturer containing a tag which binds to the solid phase and capable of binding to the bioparticle, and a detector capable of binding to the bioparticle and containing a labeled substance. A part or the whole of the complex may be dissociated from the solid phase to prepare a measurement sample containing a part or the whole of the complex not fixed on the solid phase, and signals from the measurement sample may be detected by a particle analyzer.

Abstract: The present disclosure relates to a bioparticle measuring method including forming on a solid phase a complex of a sample containing a bioparticle sampled from a specimen, a capturer containing a tag which binds to the solid phase and capable of binding to the bioparticle, and a detector capable of binding to the bioparticle and containing a labeled substance. A part or the whole of the complex may be dissociated from the solid phase to prepare a measurement sample containing a part or the whole of the complex not fixed on the solid phase, and signals from the measurement sample may be detected by a particle analyzer.

Abstract: Disclosed is a method for measuring an A? peptide, comprising: mixing a blood sample comprising an A? peptide and an antibody that specifically binds to the A? peptide to form a complex of the A? peptide and the antibody; releasing the AP peptide from the complex with a basic solution comprising an organic solvent; and measuring the released A? peptide by mass spectrometry.

Abstract: Disclosed is a method for measuring an A? peptide in a blood sample in vitro, comprising: measuring the A? peptide by an immunoassay using an antibody set comprising a capture antibody and a detection antibody that specifically bind to the A? peptide, wherein the capture antibody is an antibody that binds to an epitope comprising an N-terminal residue of the A? peptide, the detection antibody is an antibody that binds to an epitope different from the epitope to which the capture antibody binds, and the A? peptide is at least one selected from the group consisting of A?40 or A?42.

Abstract: The present invention addresses the problem of providing a method and a reagent for measuring the uptake capacity of a lipoprotein with higher accuracy. This problem is solved by preparing a lipoprotein incorporating a labeled sterol, by mixing the lipoprotein in a sample and the labeled sterol in the presence of a surfactant having no cyclic structure, and measuring the uptake capacity of the labeled sterol of the lipoprotein.

Abstract: Disclosed is a bioparticle measuring method including: detecting signal from a first measurement sample and signal from a second measurement sample, wherein the first measurement sample is prepared by mixing: a first sample containing a bioparticle sampled from a specimen; and a detector capable of binding to the bioparticle and containing a labeled substance, in the presence of an inhibitor capable of binding to the bioparticle and containing none of the labeled substance, and the second measurement sample is prepared by mixing: a second sample sampled from the same specimen independently from the first sample; and the detector, under a condition that the inhibitor is substantially absent; and calculating a measurement result of the bioparticle from a detection result of the signals from the first measurement sample and a detection result of the signals from the second measurement sample.

Abstract: Disclosed is a bioparticle measuring method including forming on a solid phase a complex of a sample containing a bioparticle sampled from a specimen, a capturer containing a tag which binds to the solid phase and capable of binding to the bioparticle, and a detector capable of binding to the bioparticle and containing an labeled substance; dissociating a part or a whole of the complex from the solid phase to prepare a measurement sample containing a part or a whole of the complex not fixed on the solid phase; and detecting signals from the measurement sample by a particle analyzer.

Abstract: Provided is a monoclonal antibody or antigen-binding fragment thereof which binds to a peptide consisting of 51st to 110th amino acid sequence or a peptide consisting of 201st to 267th amino acid sequence of an amino acid sequence of SEQ ID NO: 1, and is capable of binding to high-density lipoproteins of (1) to (3) below; (1) high-density lipoprotein that is oxidatively modified, (2) high-density lipoprotein that is not oxidatively modified, and (3) high-density lipoprotein incorporating labeled cholesterol.

Abstract: The present invention relates to a method for assisting recurrence risk prediction for hepatocellular carcinoma patients. The method comprises measuring glypican 3 (GPC3) peptide recognized by both a first monoclonal antibody and a second monoclonal antibody in a blood sample of a hepatocellular carcinoma patient, by contacting the sample with the first monoclonal antibody that recognizes a peptide having an amino acid sequence in the N-terminal side of GPC3 and the second monoclonal antibody that recognizes a peptide having an amino acid sequence in the C-terminal side of GPC3, and detecting the complex comprising GPC3 peptide, the first antibody and the second antibody.